Latest Continuous Disclosure News

Page 2 of 71
Terramin Australia faces an ASX compliance test after lodging a director interest notice seven days after the exchange says it was due. The company must explain the delay and its disclosure controls by 4 November or risk a trading halt or suspension.
Maxwell Dee
Maxwell Dee
2 Nov 2026
Australian Mines has told ASX it is unaware of undisclosed information behind a sharp increase in trading, while confirming that Boa Vista gold samples are still awaiting assay results. The company points instead to renewed scandium interest, promotional activity and its proposed corporate rebrand.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Elixir Energy has told ASX that its $205 million strategic farm-out with Beach Energy was material price-sensitive information and became disclosable when documents were signed. The company says it released the deal before trading resumed and remained compliant with continuous disclosure rules.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Eve Health Group (ASX:EVE) says it knows of no undisclosed information that would explain a sharp fall and surge in trading volume. The company suggested selling by a formerly associated shareholder may have contributed, without identifying the seller or quantifying the disposal.
Victor Sage
Victor Sage
26 Oct 2026
Queste Communications is seeking shareholder approval to leave the ASX, arguing that limited trading, concentrated ownership and listing costs no longer justify its quoted status. If approved and accepted by ASX, trading could end on 29 December 2026, leaving shareholders to sell privately after delisting.
Victor Sage
Victor Sage
26 Oct 2026
Bougainville Copper has asked the ASX to reinstate quotation trading after lodging its delayed half-year report, but the exchange has not yet approved a resumption. The company has acknowledged repeated reporting failures and introduced tighter internal controls.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Reedy Lagoon has issued 1.44 billion shares at $0.00125 each, completing the shareholder-approved placement and injecting approximately $1.8 million before costs. The Section 708A notice clears the shares for trading without further disclosure, but the filing leaves the enlarged capital structure and use of funds unstated.
Maxwell Dee
Maxwell Dee
23 Oct 2026
CSL has been named as the defendant in a group proceeding filed in the Supreme Court of Victoria, covering investors who acquired certain securities between February 2025 and May 2026. The company denies liability and says it will vigorously defend allegations involving continuous disclosure and FY26 performance statements.
Ada Torres
Ada Torres
22 Oct 2026
PARKD has completed an A$800,000 placement to strategic investors, issuing 22.86 million new shares at 3.5 cents each. The capital raise is now settled, but existing shareholders face dilution as the company funds its next phase of expansion.
Victor Sage
Victor Sage
21 Oct 2026
Avecho Biotechnology has told the ASX it is unaware of any undisclosed information that could explain a sharp move in its share price and a significant increase in trading volume. The company also confirmed compliance with continuous disclosure rules after responding to an exchange price query.
Ada Torres
Ada Torres
21 Oct 2026
Clime Capital has begun a valuation and private debt review after KPMG qualified its FY26 audit over $36.2 million of unlisted unit trusts. The company says it has not identified a material adverse change, but any adjustment to asset values, fees or receivables remains unresolved.
Claire Turing
Claire Turing
19 Oct 2026
Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.
Victor Sage
Victor Sage
16 Oct 2026

Browse the archive

Full archive